top of page

ASGCT 2026: Tevard Biosciences' suppressor tRNA programs could have the potential to treat genetic diseases more broadly than the way we traditionally think of drug development

  • May 14
  • 1 min read

Co-Founder and CEO Daniel Fischer describes how Tevard is harnessing tRNA for drug development against muscular dystrophies, cardiomyopathies, and epilepsies. The company could run basket trials and possibly earn flexible labels because these tRNAs are targeting a class of mutations rather than specific genes.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page